US · CLNN · BIOTECHNOLOGY
Clene Inc. (CLNN) intrinsic value and stock valuation
$3.52as of 2026-11-21 · Mkt cap 55.46M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Clene Inc. DCF and intrinsic value
InvestorsCraft values CLNN with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from CLNN’s statements →
Clene Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Ovid Therapeutics Inc. (OVID) $2.20
- Shattuck Labs, Inc. (STTK) $4.46
- Zentalis Pharmaceuticals, Inc. (ZNTL) $1.36
- MacroGenics, Inc. (MGNX) $1.96
- Whitehawk Therapeutics Inc (WHWK) $3.07
- Oramed Pharmaceuticals Inc. (ORMP) $3.57
- Connect Biopharma Holdings Limited (CNTB) $0.59
- Coya Therapeutics, Inc. (COYA) $2.95
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $200K | $340K | $650K | $470K | $720K |
| Operating income | -$-23.08M | -$-33.09M | -$-40.54M | -$-48.41M | -$-49.98M |
| Net income | -$-26.17M | -$-39.4M | -$-49.5M | -$-29.92M | -$-9.74M |
| EPSd | -$-2.65M | -$-5.67M | -$-9.43M | -$-9.18M | -$-3.16M |
| Operating cash flow | -$-18.55M | -$-21.33M | -$-30.17M | -$-39.01M | -$-34.62M |
| Capital expenditure | -$-40K | -$-10K | -$-330K | -$-5.18M | -$-1.33M |
| Free cash flow | -$-18.59M | -$-21.34M | -$-30.5M | -$-44.19M | -$-35.96M |
| Total assets | $18.1M | $27.3M | $52.3M | $44.5M | $63.1M |
| Total debt | $21.7M | $20.8M | $32.2M | $31.8M | $24M |
| Net debt | $16.5M | $8.69M | $3.34M | $13.5M | -$-26.25M |
| Total equity | -$-17.59M | -$-8.86M | $13.4M | $3.24M | $12.6M |
| Cash and short-term investments | $5.19M | $12.2M | $35M | $23.3M | $50.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $200K | $340K | $650K | $470K | $720K |
| Cost of revenue | $40K | $70K | $120K | $30K | $290K |
| Gross profit | $160K | $270K | $530K | $450K | $430K |
| Research and development expenses | $14M | $20.1M | $26.7M | $31.9M | $28.4M |
| Selling, general and administrative expenses | $9.23M | $13.3M | $14.4M | $16.2M | $18.8M |
| Other expenses | $0.00 | $0.00 | $0.00 | $770K | $3.18M |
| Operating expenses | $23.2M | $33.4M | $41.1M | $48.9M | $50.4M |
| Cost and expenses | $23.3M | $33.4M | $41.2M | $48.9M | $50.7M |
| Interest income | $220K | $860K | $1.39M | $0.00 | $0.00 |
| Interest expense | $2.68M | $4.06M | $4.56M | $3.3M | $870K |
| Depreciation and amortization | $1.5M | $1.65M | $1.71M | $1.02M | $950K |
| Ebitda | -$-22M | -$-33.69M | -$-43.24M | -$-25.6M | -$-8.34M |
| Operating income | -$-23.08M | -$-33.09M | -$-40.54M | -$-48.41M | -$-49.98M |
| Total other income/expenses, net | -$-3.09M | -$-6.31M | -$-8.96M | $18.5M | $39.8M |
| Income before tax | -$-26.17M | -$-39.4M | -$-49.5M | -$-29.92M | -$-10.17M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | -$-430K |
| Net income | -$-26.17M | -$-39.4M | -$-49.5M | -$-29.92M | -$-9.74M |
| Weighted average shares outstanding | $9.86M | $6.95M | $5.25M | $3.26M | $3.08M |
| Weighted average diluted shares outstanding | $9.86M | $6.95M | $5.25M | $3.26M | $3.08M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $5.19M | $12.2M | $35M | $23.3M | $50.3M |
| Net receivables | $590K | $390K | $1.34M | $2.97M | $1.61M |
| Inventory | $40K | $70K | $40K | $40K | $40K |
| Total current assets | $8.98M | $16.2M | $38.9M | $29.2M | $54.6M |
| Property, plant and equipment, net | $9.1M | $11.1M | $13.4M | $15.2M | $8.42M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $60K | $60K | $0.00 | $60K | $60K |
| Total non-current assets | $9.15M | $11.2M | $13.5M | $15.3M | $8.48M |
| Total assets | $18.1M | $27.3M | $52.3M | $44.5M | $63.1M |
| Accounts payable | $890K | $1.24M | $1.5M | $3.01M | $1.92M |
| Short-term debt | $4.88M | $1.28M | $20.1M | $6.98M | $490K |
| Deferred revenue | $1.51M | $2.67M | $0.00 | $520K | $520K |
| Total current liabilities | $10.8M | $10.3M | $25.3M | $13.9M | $6.03M |
| Long-term debt | $16.8M | $19.6M | $12.1M | $24.8M | $23.6M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $25M | $25.9M | $13.6M | $27.4M | $44.4M |
| Capital lease obligations | $4.06M | $5.06M | $5.51M | $6.15M | $4.96M |
| Total liabilities | $35.7M | $36.2M | $39M | $41.3M | $50.5M |
| Common stock | $0.00 | $0.00 | $10K | $10K | $10K |
| Retained earnings | -$-308.3M | -$-282.12M | -$-242.72M | -$-193.22M | -$-163.3M |
| Accumulated other comprehensive income (loss) | $170K | $70K | $200K | $200K | $230K |
| Total equity | -$-17.59M | -$-8.86M | $13.4M | $3.24M | $12.6M |
| Total investments | $60K | $60K | $6.18M | $5.04M | $60K |
| Total debt | $21.7M | $20.8M | $32.2M | $31.8M | $24M |
| Net debt | $16.5M | $8.69M | $3.34M | $13.5M | -$-26.25M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-26.17M | -$-39.4M | -$-49.5M | -$-29.92M | -$-9.74M |
| Depreciation and amortization | $1.5M | $1.65M | $1.71M | $1.02M | $950K |
| Stock-based compensation | $6.38M | $7.95M | $9.12M | $8.51M | $12.4M |
| Change in working capital | -$-3.35M | $3.21M | -$-190K | -$-1.54M | $1M |
| Accounts receivable | $60K | $80K | $50K | -$-140K | -$-30K |
| Inventory | $30K | -$-30K | $10K | -$0.00 | $150K |
| Accounts payable | -$-350K | -$-260K | -$-1.51M | $280K | $1.27M |
| Net cash provided by operating activities | -$-18.55M | -$-21.33M | -$-30.17M | -$-39.01M | -$-34.62M |
| Investments in property, plant and equipment | -$-40K | -$-10K | -$-330K | -$-5.18M | -$-1.33M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-40K | $6.32M | -$-1.5M | -$-10.16M | -$-1.33M |
| Common stock issued | $10.4M | $9.24M | $42.1M | $11.5M | $9.25M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $11.5M | -$-1.53M | $42.2M | $17.3M | $27.1M |
| Net change in cash | -$-6.97M | -$-16.67M | $10.5M | -$-31.96M | -$-8.93M |
| Cash at end of period | $5.25M | $12.2M | $28.9M | $18.4M | $50.4M |
| Operating cash flow | -$-18.55M | -$-21.33M | -$-30.17M | -$-39.01M | -$-34.62M |
| Capital expenditure | -$-40K | -$-10K | -$-330K | -$-5.18M | -$-1.33M |
| Free cash flow | -$-18.59M | -$-21.34M | -$-30.5M | -$-44.19M | -$-35.96M |
Line items
Line items
Line items
About Clene Inc.
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.
- CEO
- Robert Etherington
- Employees
- 79
- Beta
- 0.92
Explore
Frequently asked questions
What is the intrinsic value of Clene Inc. (CLNN)?
Clene Inc. (CLNN) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is CLNN undervalued?
CLNN trades at a price of $3.52 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.